The FDA is proposing to delay the effective date of the amendments to the existing medical product “intended use” regulations to allow further consideration of the substantive issues raised in the comments received. As per the Federal Register of January 9, 2017, the final rule added a new regulation (§ 1100.5) to title 21 of the CFR to describe the circumstances in which a product made or derived from tobacco that is intended for human consumption will be subject to regulation as a drug, device, or a combination product under the Federal Food, Drug, and Cosmetic Act (FD&C Act). The effective date of the final set rule was finally set as until March 19, 2018, as the FDA reopened the docket to invite additional public comment on the rule and will consider the comments submitted to prepare and publish a final notification of the delay.
Recent News
Roundup Lawsuits in New Jersey Seek Centralization
03/04/2024 - 17:33
A request has been filed by a group of plaintiffs urging the consolidation of all Roundup lawsuits related to non-Hodgkin’s lymphom…
Learn More
Baltimore Settles in Walmart Opioid Cases
03/03/2024 - 20:48
The mayor of Baltimore, representing the City, has endorsed a statewide settlement with Walmart to address the corporation's allege…
Learn More
Opioid Crisis: Fentanyl and Meth Drive 'Fourth Wave…
02/27/2024 - 21:02
The United States is currently grappling with what some experts identify as the "fourth wave" of the opioid epidemic, presenting in…
Learn More
Oregon Re-evaluates Decriminalization Amid Opioid Crisis
02/20/2024 - 16:46
In 2020, Oregonians approved a groundbreaking ballot measure, known as Measure 110, establishing the most progressive drug law in t…
Learn More